Treatment protocols Diseases
Stroke CP ALS SCI PD Autism Dementia MS
Total number of treated patients 23 38 19 19 15 16 18 52
Subcutaneous medications
Filgrastim 15μg/Kg/d 15 26 16 15 10 11 11 26
Erythropoietin 100 U/Kg/d 13 - - - - - - -
Intravenous medications
Cerebrolysin Before ASCT 1ml/5kg/6h 7 23 7 5 5 4 12 28
After ASCT 20 30 13 7 11 7 16 40
Citicoline Before ASCT 10mg/kg/6h 14 17 5 - 8 5 7 22
After ASCT 18 28 10 5 10 10 16 35
Per os medications
Citicoline Solution 1ml/10kg/d 16 25 6 8 7 10 13 30
Cytidine 5'Monophosphate Uridine Triphosphate 1mg/6Kg/d
1mg/10Kg
16 12 12 8 6 7 12 26
Adenosine Triphosphate 1mg/Kg/d 14 8 7 6 9 5 10 15
Omega 3 20mg/ Kg/d 16 19 10 4 6 7 15 37
Vimpocetine
Huperzine A
Lecithin
10mg/d
100 mcg/d
100 mg/d
16 27 12 12 7 10 13 33
Atorvastatin 20 mg/d 8 - - - - - - -
Technical
Bone marrow needle 1.5 mm 11 20 6 11 9 9 7 25
2.0 mm 12 18 13 8 6 7 11 27
Biopsy site
(iliac crest)
Unilateral posterior superior 2 10 3 3 3 4 2 10
Posterior Superior 18 20 14 5 10 10 12 29
Posterior Superior + Anterior 3 8 2 11 2 2 4 13
Incubation Period short 17 22 14 10 9 8 11 35
medium 4 12 4 7 4 5 5 11
long 2 4 1 2 2 3 3 6
Temperature 4-8 °C 3 8 2 4 4 2 6 5
20-24 °C 15 24 13 10 9 10 5 33
37 °C 5 6 4 5 2 4 7 14
Agent Eco-ultrafiltrate 17 17 11 9 6 6 11 25
Shaker 10 16 7 9 5 6 8 12
Procedural
Infusion route Intravenous 3 4 2 - 3 4 2 5
lumbar puncture 3 5 3 11 3 3 2 6
Intravenous + lumbar puncture 17 29 14 8 9 9 14 41
Mannitol 20% intravenous bolus 19 22 11 6 9 4 16 34
Trendelenburg position 1 h 7 9 15 - 6 5 11 24
3 h 12 16 2 - 4 7 4 19
10 h 4 13 2 - 5 4 3 9
Late and long-term measures
Hyperbaric oxygen therapy ­- 12 - - - 6 -
Neurorehabilitation and neuroreeducation 15 33 15 17 5 8 - 46
MS – Multiple Sclerosis
PD – Parkinson Disease
CP – Cerebral Palsy
SCI – Spinal Cord Injury
ALS – Amyotrophic Lateral Sclerosis
Table 3: Variety of treatment protocols applied to all categories of patients.